B
Benitec Biopharma Inc.
BNTCCIK 0001808898NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30
Period
FY 2025
Revenue
—
Net Income
$-37.90M
Total Assets
$99.59M
Equity
$97.30M
Shares Out
34.35M
Op. Cash Flow
$-23.60M
Business
Benitec Biopharma Inc. is a clinical‑stage biotechnology company focused on discovery, development and commercialization of genetic medicines using a DNA‑directed RNA interference (ddRNAi) “silence and replace” platform. It develops AAV‑based gene therapy constructs that chronically express shRNA/miRNA molecules to silence disease‑causing genes and simultaneously deliver codon‑optimized wildtype replacement genes, with lead product BB‑301 targeting PABPN1 for OPMD. Its business comprises research and clinical development of ddRNAi and silence‑and‑replace product candidates, intellectual property licensing, and outsourced manufacturing and strategic collaborations for co‑development. Clinical development is currently conducted in the United States while it seeks global regulatory approvals and intends to use third‑party manufacturers and partner distribution channels for broader commercialization.
Summary from filing dated 2025-09-22
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Royalties and license fees | 0 | −108,000 | 0 | 9,000 | 123,000 | |
| Research and development | 18 | 16 | 13 | 11 | 7 | |
| General and administrative | 23 | 7 | 6 | 7 | 7 | |
| Total operating expenses | 42 | 22 | 19 | 18 | 14 | |
| Loss from operations | −42 | −22 | −19 | −18 | −14 | |
| Foreign currency transaction gain (loss) | −71,000 | 40,000 | −415,000 | −232,000 | −333,000 | |
| Interest income (expense), net | 3 | 904,000 | −33,000 | −32,000 | −6,000 | |
| Other expense, net | −131,000 | −204,000 | −30,000 | −79,000 | 37,000 | |
| Gain on extinguishment of liabilities | 764,000 | 0 | — | — | — | |
| Unrealized loss on investment | 0 | −1,000 | −3,000 | −11,000 | 16,000 | |
| Total other income (loss), net | 4 | 739,000 | −481,000 | −354,000 | −286,000 | |
| Net loss | −38 | −22 | −20 | −18 | −14 | |
| Unrealized foreign currency translation gain (loss) | 53,000 | −62,000 | 415,000 | 210,000 | 498,000 | |
| Total other comprehensive income (loss) | 53,000 | −62,000 | 415,000 | 210,000 | 498,000 | |
| Total comprehensive loss | −38 | −22 | −19 | −18 | −13 | |
| Deemed dividends | 0 | −619,000 | 0 | — | — | |
| Net loss attributable to common shareholders | −38 | −22 | −20 | — | — | |
| Net loss per share: basic | −1.05 | −1.22 | −14.12 | −37.88 | −3.23 | |
| Net loss per share: diluted | −1.05 | −1.22 | −14.12 | −37.88 | −3.23 | |
| Weighted average number of shares outstanding: basic | 36 | 18 | 1 | 480,688 | 4 | |
| Weighted average number of shares outstanding: diluted | 36 | 18 | 1 | 480,688 | 4 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2024 2024-03-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 98 | 51 | — | — | — | |
| Restricted cash | 113,000 | 63,000 | — | — | — | |
| Trade and other receivables | 33,000 | 229,000 | — | — | — | |
| Prepaid and other assets | 628,000 | 516,000 | — | — | — | |
| Total current assets | 99 | 52 | — | — | — | |
| Property and equipment, net | 131,000 | 179,000 | — | — | — | |
| Deposits | 55,000 | 25,000 | — | — | — | |
| Prepaid and other assets | 28,000 | 62,000 | — | — | — | |
| Right-of-use assets | 860,000 | 270,000 | — | — | — | |
| Total assets | 100 | 52 | — | — | — | |
| Trade and other payables | 1 | 4 | — | — | — | |
| Accrued employee benefits | 426,000 | 475,000 | — | — | — | |
| Lease liabilities, current portion | 354,000 | 284,000 | — | — | — | |
| Total current liabilities | 2 | 5 | — | — | — | |
| Non-current accrued employee benefits | 0 | 38,000 | — | — | — | |
| Lease liabilities, less current portion | 495,000 | 0 | — | — | — | |
| Total liabilities | 2 | 5 | — | — | — | |
| Preferred stock, $0.0001 par value5,000,000 shares authorized; no shares issued and outstanding at June 30, 2025 and 2024, respectively | 0 | 0 | — | — | — | |
| Common stock, $0.0001 par value160,000,000 shares authorized; 26,250,469 shares and 10,086,119 shares issued and outstanding at June 30, 2025 and 2024, respectively | 2,000 | 1,000 | — | — | — | |
| Additional paid-in capital | 326 | 238 | 198 | 198 | 198 | |
| Accumulated deficit | −228 | −190 | −186 | −181 | −174 | |
| Accumulated other comprehensive loss | −839,000 | −892,000 | — | — | — | |
| Total stockholders' equity | 97 | 47 | — | — | — | |
| Total liabilities and stockholders' equity | 100 | 52 | — | — | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 66,000 | 87,000 | 136,000 | 167,000 | 231,000 | |
| Amortization of right-of-use assets | 330,000 | 256,000 | 245,000 | 225,000 | 193,000 | |
| Share-based compensation expense | 17 | 830,000 | 452,000 | 870,000 | 634,000 | |
| Trade and other receivables | 197,000 | −176,000 | −50,000 | 1,000 | 28,000 | |
| Prepaid and other assets | −111,000 | 645,000 | −414,000 | 62,000 | −4,000 | |
| Trade and other payables | −2 | 941,000 | 1 | 1 | 55,000 | |
| Accrued employee benefits | −81,000 | 39,000 | 73,000 | 80,000 | 121,000 | |
| Lease liabilities | −356,000 | −275,000 | −252,000 | −196,000 | −192,000 | |
| Net cash used in operating activities | −24 | −19 | −18 | −16 | −13 | |
| Purchase of property and equipment | −18,000 | −179,000 | −1,000 | −13,000 | −221,000 | |
| Net cash used in investing activities | −18,000 | −179,000 | −1,000 | −13,000 | −221,000 | |
| Proceeds from issuance of common stock, pre-funded warrants, and common warrants | 30 | 71 | 18 | — | — | |
| Proceeds from exercise of pre-funded warrants, Series 2 warrants common warrants | 42 | 3 | — | — | — | |
| Share and pre-funded warrants issuance transaction costs | −2 | −6 | −2 | — | — | |
| Net cash provided by financing activities | 70 | 68 | 16 | — | 23 | |
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash | 49,000 | −8,000 | 412,000 | 204,000 | 499,000 | |
| Net increase in cash, cash equivalents, and restricted cash | 47 | 48 | −2 | −16 | 10 | |
| Initial measurement of operating lease right-of-use assets and liabilities | 255,000 | 0 | — | — | — | |
| Re-measurement of operating lease right-of-use assets and liabilities | 666,000 | 0 | — | — | — | |
| Deemed dividend | 0 | 619,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro